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Abstract 
Objectives: Benefits from HAART may be heterogeneous across HIV-infected individuals. 
We measured the differences in the rate of HAART failure across the various subgroups 
represented at the level of a country. 
Design: We used data from a national representative sample of people living with HIV and 
followed at hospital in France (ANRS-EN12-VESPA survey). 
Methods: Analyses were restricted to the 896 participants on HAART for ≥6 months and 
antiretroviral-naïve at HAART initiation. Different indicators of treatment failure were 
defined: immunologic failure (absence of increase of ≥100 CD4 cell/mm
3
); immuno-virologic 
failure (CD4 cell count≤200/mm
3
 and detectable HIV-RNA); clinical failure (occurrence of 
an AIDS-defining illness >3 months after HAART initiation). Differences in the frequency of 
treatment failure across the various subgroups were measured using logistic regression 
models adjusted for major established determinants of response to HAART 
Results: Overall, 19.6% of the study participants experienced immunologic failure, 3.4% 
immuno-virologic failure, and 3.0% clinical failure, with substantial variations across the 
various subgroups. Compared to homo/bisexual males, migrants had higher rates of 
immunologic failure (respectively, adjusted odds-ratio 2.27, 95% confidence interval [1.14-
4.56] for migrant males and 2.19 [1.17-4.08] for migrant females), of immuno-virologic 
failure (respectively, 8.23 [1.77-38.33] and 6.91 [1.03-46.32]), and of clinical failure 
(respectively, 4.60 [1.01-20.86] and 4.22 [0.84-21.17]). 
Conclusions: In France, migrants consistently appear to be at increased risk of immunologic, 
immuno-virologic and clinical treatment failure compared to the other HIV-infected 
individuals. Understanding the reasons underlying such heterogeneity in terms of living 
conditions and educational/cultural background appears to be important. 
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Introduction 
In the era of highly active antiretroviral therapies (HAART), the magnitude of 
immunological and virological responses to treatment constitute strong predictors of disease 
progression and death among HIV-1-infected patients [1, 2]. Response to HAART has been 
shown to be influenced by various factors including characteristics at the time of HAART 
initiation (HIV disease advancement [2]; history of suboptimal antiviral treatment [3]), 
treatment characteristics (HAART duration [4]; level of adherence [5]; experience of 
treatment discontinuation [6]), sociodemographics (age [7]; gender [8]), comorbidity 
(depression [9]; HCV coinfection [10]) and ongoing drug use [11]. 
In Western countries, the HIV-infected population is made up of diverse subgroups 
characterized by highly contrasted socioeconomic and cultural backgrounds [12]. 
Longitudinal studies have suggested that after accounting for major established risk factors of 
treatment failure, benefits from HAART may be heterogeneous across these different 
subgroups. A lower beneficial impact of HAART on the risk of disease progression and/or 
death has been reported among persons with a history of injecting drug use (IDU) [4] and 
among migrants [13], while homosexual men may have benefited from HAART more than 
the others [14].  
However, such differences have not been reported consistently across studies. This may be 
due to methodological concerns including the exclusion of some categories of individuals 
from the study samples, or the inadequate accounting for acknowledged determinants of 
treatment failure. 
The present study aimed at measuring the differences in the rate of failure to HAART across 
the various subgroups of HIV-infected persons represented at the level of a country, 
accounting for subgroups differences in major established determinants of response to 
HAART. We used data from a French national representative sample of people living with 
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HIV and followed at hospital. In France, access to care for HIV infection is universal and, 
since antiretroviral treatments are provided exclusively through hospital physicians’ 
prescription, HIV infection is almost exclusively managed through hospital outpatient clinics, 
regardless of disease severity [15]. The sample we used has been constituted specifically with 
the concern for reflecting the diversity of the HIV epidemic in terms both of individuals’ and 
disease management characteristics, thus allowing us to account for the great heterogeneity in 
situations encountered at the country level.  
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Material and Methods 
Study design 
We used data from the ANRS-EN12-VESPA study, a large survey aimed at studying the 
social situation and living conditions of HIV-infected persons in France. The study design has 
been detailed elsewhere [16]. Data were collected between December 2002 and September 
2003 among a random stratified sample of 4,963 HIV-infected outpatients recruited in 102 
French hospital departments delivering HIV care. The stratification criteria were departments’ 
geographic location and size of HIV caseload. Eligible individuals were those diagnosed as 
being HIV1-infected for at least six months, aged 18 or older, and, for non-French citizens, 
living in France for at least six months. In the participating departments, physicians invited a 
sample of HIV-infected outpatients, randomized according to the order in which they were 
received, to participate in the study. Those with very poor understanding of the French 
language were excluded. 
Individuals who agreed to participate signed an informed consent and answered a face-to-
face standardized questionnaire administered by a trained interviewer, using the CAPI system 
(Computer Assisted Personal Interview). Detailed information was collected on individuals’ 
sociodemographic characteristics and on the different aspects of their life with HIV including 
access to and use of the healthcare system, health behaviors, occupational status, income, 
housing, social support, HIV disclosure, HIV-related discriminations, sexual activity and 
reproductive life. This information concerned both the situation at the time of the study and 
that at the time of HIV diagnosis; major changes occurred during the course of the disease 
were collected, providing retrospective information on participants’ social trajectory during 
the course of the disease. Median length of interview was 40 minutes. After interview 
completion, participants received a 15€ voucher and were asked to fill in an additional self-
administered questionnaire including psychometric scales. Information on health status, 
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including characteristics of HIV infection and its management at the time of the study and 
retrospectively since diagnosis and HCV serostatus was documented from medical records.  
The study reached the ethical requirements of the French “Commission Nationale 
Informatique et Libertés”. 
Data collected 
Among 4,963 eligible individuals, 2,932 participants were included in the study. Two 
hundred and sixty four were not solicited because of major cognitive impairment or health 
problems, while 1,767 declined to participate. Individuals who refused most frequently cited a 
lack of time; compared to participants, they were more likely to have been HIV-infected 
through a way other than homo/bisexual contacts and to be employed at the time of the study.  
Weighting procedure 
Non participation was 41% of the randomized individuals overall, with substantial 
differences according to HIV transmission category, employment status and immunological 
status. Major socio-demographic and health-related characteristics were collected both among 
respondents and non-respondents, allowing for a weighting procedure to take into account this 
participation bias. This weighting procedure included two steps: first, considering the unequal 
probability of enrolment related to the heterogeneous frequency of hospital visits, a weight 
was attributed to each individual corresponding to the inverse number of hospital visits 
he(she) had reported for the preceding year; second, to account for non-response, an 
additional weight was computed, using a method of calibration adjustment [17], in such a way 
that the weighted distribution of the participants regarding transmission group, employment 
status and immunological status was comparable to that of the entire eligible population. 
Variables of interest 
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Different indicators of treatment failure were defined using data from the medical records. 
Immunologic failure was defined as the absence of increase of ≥100 CD4 cell/mm
3
 between 
HAART initiation and the time of data collection. Immuno-virologic failure was defined as 
the combination of a CD4 cell count≤200/mm
3
 and a detectable HIV-RNA at the time of data 
collection. Participants who had developed a first AIDS-defining illness after a period of >3 
months on HAART were considered to be in clinical failure. HAART was defined as the 
concomitant receipt of at least 3 antiretrovirals. 
Based on the characteristics of the HIV epidemic in western Europe [12], participants were 
divided in seven subgroups corresponding to the most significant groups of persons living 
with HIV infection in France: homo/bisexual males, IDU heterosexual males, IDU females, 
French-native heterosexual males without history of IDU, French-native females without 
history of IDU, migrant heterosexual males without history of IDU, and migrant females 
without history of IDU. Non French-natives who did not have French nationality at birth were 
classified as migrants. These seven subgroups constitute homogeneous epidemiological 
entities regarding HIV transmission [12] and show marked differences in socioeconomic 
characteristics and living conditions [18]. 
Data also included information on the following established determinants of response to 
HAART: 1) data from medical records, i.e. CD4 cell count, HIV-RNA and AIDS at HAART 
initiation; time since first HAART initiation and HAART regimen prescribed at the time of 
data collection; date of HIV diagnosis; and HCV coinfection; 2) depressive symptoms at the 
time of interview as measured by the Hospital Anxiety and Depression Scale (HADS) [19] 
included in the self-administered questionnaire and 3) participant-reported age and level of 
treatment adherence at the time of data collection, active drug use in the year preceding 
interview, and history of interruption of ≥6 months in HIV care since diagnosis. Adherence 
was assessed using a dichotomous indicator (“highly” versus “poorly” adherent) validated in 
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previous cohort studies [20], summarizing four questions dealing with dose taking during the 
prior week [21]. 
Statistical analyses 
Analyses were restricted to participants on HAART for at least 6 months at the time of data 
collection and antiretroviral-naïve at the time of HAART initiation. Differences in the 
frequency of each indicator of treatment failure across the various subgroups were measured 
using logistic regression models accounting for weighted data and adjusted for the major 
established determinants of response to HAART described above. Homo/bisexual males were 
used as the reference group. All statistical analyses were performed using Stata 9.0
®
 (Stata 
Corporation, College Station, TX). 
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Results 
Study population 
Overall, 1939 participants had been on HAART for at least 6 months at the time of the 
study, among whom 896 were antiretroviral-naïve at HAART initiation. Of these 896, 38.4% 
were homo/bisexual men, 27.3% were French-native heterosexuals (16.9% males, 10.4% 
females), 22.3% were migrant heterosexuals (11.0% males, 11.3% females) and 12.0% were 
IDU (8.7% males, 3.3% females). The majority of the heterosexual migrants originated from 
Sub-Saharan Africa (76.3% of the males and 82.3% of the females). 
As shown in Table 1, these various subgroups showed marked differences on established 
determinants of response to HAART. Migrant heterosexual females (median age 33 years), 
were younger than the other groups while French-native heterosexual males were the oldest 
(median age 47 years). The majority (73.3%) of the IDU participants had been diagnosed as 
being HIV-infected in the pre-HAART era, while this was the case for only one third of the 
homo/bisexual males and French-native heterosexuals and 13.3% of the migrants. Similarly, 
individuals with a history of IDU had spent the longest time on HAART at the time of data 
collection (57 months in median) and migrants the shortest time (32 months). At the time of 
data collection, 25.2% of the participants were prescribed a regimen including a protease 
inhibitor and 46.4% a non-nucleoside reverse transcriptase inhibitor, without difference across 
subgroups. At HAART initiation, French-native heterosexuals males, IDU and migrants were 
more likely than homo/bisexual males and French-native heterosexuals females to have a 
marked immunodeficiency (CD4<200/mm
3
); French-native heterosexuals males were also 
more likely to have reached the AIDS stage. Compared to the other subgroups, IDU 
participants more frequently reported a history of interruption in HIV care (33.8% vs. 6.3%) 
and current drug use at the time of the study (27.2% vs. 0.3%); they were also more likely to 
be HCV-coinfected (88.0% vs. 6.4%) and to present symptoms of depression (22.1% vs. 
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12.5%). Migrants reported suboptimal adherence more frequently than the other participants 
in this study (56.1% vs. 34.6%). 
Differences in treatment failure rates across subgroups 
Overall, 19.6% of the study participants experienced immunologic failure, 3.4% immuno-
virologic failure, and 3.0% clinical failure. As shown in Table 2, these rates showed 
substantial variations across the various subgroups: immunologic failure rate ranged from 
10.6% among French-native heterosexual males to 37.5% among migrant females; immuno-
virologic failure rate from 0% among IDU females to 9.2% among IDU males; and clinical 
failure rate from 0.6% among French-native heterosexual females to 9.1% among IDU males. 
Multivariate analysis accounting for subgroups differences in major established 
determinants of response to HAART suggested that compared to homo/bisexual males, 
migrants had higher rates of immunologic failure (respectively, adjusted odds-ratio 2.27, 95% 
confidence interval [1.14-4.56] for migrant males and 2.19 [1.17-4.08] for migrant females), 
of immuno-virologic failure (respectively, 8.23 [1.77-38.33] and 6.91 [1.03-46.32]), and of 
clinical failure (respectively, 4.60 [1.01-20.86] and 4.22 [0.84-21.17]). For the other 
subgroups, the rate of HAART failure did not differ from that of the homo/bisexual males in 
multivariate analysis. The other characteristics associated with an increased rate of treatment 
failure in multivariate analysis included age≥50, time on HAART<24 months, baseline CD4 
cell count≤200/mm
3
, baseline HIV-RNA ≥100,000 copies/ml, AIDS at baseline, history of 
interruption in HIV care, suboptimal adherence, HCV coinfection and current drug use.
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Discussion 
Our results suggest that at the level of a country, here France, long-term benefits from 
antiretroviral multitherapies are not homogeneous across subgroups of the HIV-infected 
population. Heterosexual migrants consistently appear to be at increased risk of immunologic, 
immuno-virologic and clinical treatment failure compared to the other HIV-infected 
individuals, even after accounting for differences in established determinants of response to 
treatment. Considering that access to care and treatment for HIV infection is universal in 
France (as reflected in our data by the absence of difference in the type of HAART regimen 
prescribed across subgroups) and that analyses have taken into account differences in baseline 
characteristics at HAART initiation, our findings are likely to reflect a heterogeneous 
response to HAART rather than differences in access to healthcare; the latter, if they exist, 
may further increase such heterogeneity. 
The ANRS-EN12-VESPA survey, with its large randomized sample of persons living with 
HIV and followed at hospital all over France, provides a unique dataset to study the diversity 
of HIV-infected population at a national level. The retrospective design of our study has 
probably allowed for the inclusion of individuals who are likely to be underrepresented in 
studies assessing treatment outcomes prospectively. Indeed, prospective follow-up is likely to 
lead to the exclusion of the individuals with the most precarious socioeconomic conditions 
[22], implying a reduced heterogeneity across individuals with regard to these characteristics 
in the study sample compared to the diversity existing within the source population. Thus, 
prospective studies may sometimes fail to detect differences across subgroups that are 
characterized by marked differences in socioeconomic status and the contribution of other 
types of studies to the question of inequalities across subgroups appears of importance. Our 
results suggest that the significant role of major determinants of response to HAART on 
treatment failure reported in prospective studies is found as well at the population level, and 
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that additional characteristics related to foreign-nativity may also play a role, beyond that of 
the established factors. 
The interpretation of our results must remain cautious due to concerns related to the 
retrospective nature of the study. First, individuals who died between HAART initiation and 
the study were excluded from the sample. Although this point may have led to an 
underestimation of treatment failure rates in our study, it is unlikely to have influenced the 
differences we report since analyses have been adjusted for acknowledged predictors of 
treatment failure and death. Second, only few points of laboratory measures were available to 
define immuno/virologic failure. To ensure accurate indicators of response to treatment 
despite this limitation, we gave precedence to CD4 cell count measurement rather than HIV-
RNA which is highly subject to acute changes over time. Lastly, using a single cross-sectional 
measure of time-dependent phenomenons such as depressive symptoms, adherence to 
treatment and ongoing drug use has probably led us to underestimate their association with 
treatment failure. However, the established predictive role of these factors has been 
effectively found and accounted for in our analyses. Although information on the different 
regimens prescribed over time was also lacking, we took into account the duration of HAART 
treatment as a proxy for this sequencing. 
Heterosexual migrants without history of IDU account for the great majority of the non-
French native population living with HIV infection in France (85.4% in our sample) as in 
other western European countries [12]; they mostly include individuals originating from sub-
Saharan Africa (79.3%) or other non-European countries (14.0%) and are characterized by a 
recent immigration in France (median: 6 years at the time of the study). Non-heterosexual 
migrants constitute a marginal part of the HIV-infected population (homo/bisexual migrants 
account for 2.2% of our sample and IDU migrants for 1.6%); moreover, they differ from 
heterosexual migrants in that they mainly come from other European countries (respectively, 
59.4% and 52.7%) and have been settled in France for a long time (respectively, median of 13 
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and 24 years at the time of the study). For all these reasons, homo/bisexual and IDU migrants 
have not been analyzed as separate subgroups and have been classified together with French-
native homo/bisexuals and IDU, respectively, rather than with heterosexual migrants. 
Our finding of an increased risk of treatment failure among heterosexual migrants in France 
is consistent with data from the Netherlands suggesting that migrants followed in a clinic in 
Amsterdam have poorer virologic and clinical responses to HAART compared to the non-
migrants [13]. On the other hand, migrants were not found to have an impaired response to 
HAART neither in Denmark [23] nor in London [24]. These two latter studies included 
individuals regardless of history of antiretroviral treatment prior to HAART initiation; since 
history of pre-HAART treatment, a strong predictor of response to HAART, is likely to be 
distributed differentially among migrants and non migrants, differences may have been 
underestimated in these studies. 
There can be various explanations for our findings. Racial differences in viral subtypes, 
drug metabolism and levels of CD4 cell count and HIV-RNA have been shown, with a 
potential role on the magnitude and/or the measure of therapeutic response. However, studies 
have found that race does not constitute an independent predictor of HAART failure [25, 26] 
and that immuno-virologic response to HAART is comparable between persons from low- 
and high-income parts of the world [27], suggesting that racial differences are unlikely to 
explain our findings. 
Alternatively, the heterogeneity we report may result from differences in living conditions 
and educational/cultural background. HIV-infected migrants in western countries encounter 
particularly adverse socioeconomic conditions. Among participants of the ANRS-EN12-
VESPA study, precarious housing conditions and lone parenthood at the time of the study 
were more frequent among migrants than among French-natives [18]. Moreover, over half 
(53%) of the heterosexual migrants reported financial difficulties and 33% reported food 
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privation through lack of money in the preceding month, compared to 21% and 7% of the 
other participants, respectively; social isolation, as defined by <1 weekly contact with family 
members/friends, concerned 20% of the heterosexual migrants versus 12% of the others (data 
available on request). Such adverse living conditions may have indirect effects on response to 
treatment through various pathways including poor adherence, high comorbidity (e.g., 
depression, tuberculosis, bacterial coinfections), inadequate healthcare, low social support, 
life event stress, or maladaptive coping [21, 28-31]. The low level of literacy of HIV-infected 
migrants [18] may further constitute a barrier to adequate access to care and HIV treatment 
adherence and knowledge, with consequences on health status [32, 33]. Furthermore, cultural 
factors as well as the stigmas of HIV, race and ethnicity probably also influence treatment 
adherence and healthcare providers’ attitudes and interactions with their patients [34]; HIV 
stigmatization in migrants’ community may additionally result in low rates of HIV disclosure, 
with consequent low social support. Among participants of the ANRS-EN12-VESPA study, 
17% of the heterosexual migrants versus 4% of the others had kept their HIV status secret 
from their social circle.  
Our findings have important public health implications since the proportion of heterosexual 
migrants coming from countries with high HIV prevalence, especially sub-Saharan Africa, 
and living in precarious socioeconomic conditions has been rising drastically in the last few 
years [12]. Understanding the reasons underlying a poorer response to treatment in this 
population appears to be important. Although the present study precludes from drawing any 
conclusion in terms of causality, our results suggest that living conditions and 
educational/cultural background may play a major role on therapeutic failure. Further studies 
should prospectively assess the different pathways involved in such heterogeneity. 
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Table 1. Characteristics* of the 896 participants on HAART for ≥6 months and antiretroviral-naïve at HAART initiation, overall and according to subgroup. ANRS-
EN12-VESPA Study. 
 
 
Homo/bisexual 
males 
French-native 
heterosexual 
males 
French-native 
heterosexual 
females 
Migrant 
heterosexual 
males 
Migrant 
heterosexual 
females 
IDU 
males 
IDU 
females Total 
Overall  38.4 16.9 10.4 11.0 11.3 8.7 3.3 100.0 
Age (years)  Median 42 47 41 41 33 41 40 41 
 
<30 6.6 0.4 11.6 6.3 23.2 - - 7.1 
 
30-39 32.6 26.3 32.2 31.6 50.8 38.3 37.4 34.1 
 
40-49 35.8 31.2 31.6 44.2 15.2 55.6 56.8 35.6 
 
≥50 25.0 42.0 24.5 17.9 10.8 6.1 5.7 23.2 
Period of HIV diagnosis Median 1998 1998 1997 2000 2000 1991 1989 1998 
 
<1996 34.3 28.9 37.4 13.6 13.0 66.7 90.6 33.7 
 
≥1996 65.7 71.1 62.6 86.4 87.0 33.3 9.4 66.3 
Time spent on HAART (months) Median 48 43 52 33 27 57 62 44 
 
6-12 7.1 4.9 6.2 13.1 21.5 1.3 9.0 8.5 
 
12-24 13.7 17.8 8.5 13.7 21.9 8.6 3.8 14.0 
 
24-60 45.3 54.8 49.1 52.2 52.4 48.9 35.2 48.8 
 
>60 33.9 22.5 36.2 21.1 4.2 41.1 51.9 28.7 
CD4 cell count at start of HAART >350 35.0 17.7 23.8 17.5 12.1 23.6 23.4 25.0 
(/mm3) 201-350 26.7 31.8 35.5 29.6 38.5 14.3 27.6 29.1 
 
51-200 23.1 28.6 21.8 28.5 39.7 42.7 33.3 28.4 
 
≤50 15.2 21.4 18.9 24.4 9.7 19.4 15.6 17.4 
HIV RNA at start of HAART <10 000  13.9 11.2 12.7 5.6 22.9 19.4 18.0 14.0 
(copies/ml) 10 000-29 999 10.5 9.1 13.5 11.7 24.5 4.8 11.8 11.8 
 
30 000-100 000  23.1 25.9 24.3 26.6 14.7 17.7 23.5 22.7 
 
≥100 000 47.5 50.3 43.9 54.2 34.8 54.6 34.5 47.1 
 
Unknown 5.0 3.5 5.6 1.8 3.1 3.5 12.1 4.3 
AIDS at start of HAART No 76.8 66.1 78.7 69.8 81.7 78.3 79.6 75.2 
 
Yes 23.0 33.9 19.7 25.7 18.3 20.4 20.4 23.9 
 
Unknown 0.3 - 1.6 4.5 - 1.3 - 0.9 
History of interruption in HIV care No 92.8 92.6 90.5 94.0 98.0 63.9 66.0 89.8 
 
Yes 7.2 7.4 9.1 3.7 2.0 34.4 32.1 9.7 
 
Unknown - - 0.4 2.3 - 1.7 1.8 0.5 
Adherence to HAART High 61.7 76.8 75.6 46.1 41.7 49.6 59.7 60.6 
 20 
 
Poor 38.3 23.2 24.4 53.9 58.3 50.4 40.3 39.4 
HCV coinfection No 93.7 97.0 91.7 92.0 91.7 9.7 18.0 83.8 
 
Yes 6.3 3.0 8.3 8.0 8.3 90.3 82.0 16.2 
Depressive symptoms No 71.2 72.7 70.7 45.7 40.2 48.6 55.7 62.6 
 
Mild 10.3 6.3 9.1 4.2 7.7 14.0 17.7 9.1 
 
Moderate/severe 3.7 5.0 4.8 2.6 5.5 8.1 4.5 4.5 
 
Unknown 14.7 15.9 15.4 47.5 46.6 29.3 22.1 23.7 
Current drug use No 99.3 100.0 100.0 100.0 100.0 73.3 71.5 96.4 
 
Yes 0.7 - - - - 26.7 28.5 3.6 
* weighted % 
IDU: intravenous drug users 
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Table 2: Characteristics associated with treatment failure in multivariate analysis among the 896 participants on HAART for ≥6 months in 2003 and 
antiretroviral-naïve at HAART initiation. ANRS-EN12-VESPA Study. 
 
   Immunologic failure  Immuno-virologic failure  Clinical failure 
   % OR [95%CI] % OR [95%CI] % OR [95%CI] 
Overall   19.6  3.4  3.0  
Group Homo/bisexual males  16.4 1 1.4 1 1.8 1 
 French-native heterosexual males  10.6 0.73 [0.39-1.33] 4.1 2.75 [0.68-11.08] 1.8 1.23 [0.22-6.84] 
 French-native heterosexual females  13.4 0.93 [0.45-1.91] 0.9 0.63 [0.07-6.09] 0.6 0.36 [0.02-5.96] 
 Migrant heterosexual males  27.4 2.27 [1.14-4.56] * 6.7 8.23 [1.77-38.33] * 5.6 4.60 [1.01-20.86] * 
 Migrant heterosexual females  37.5 2.19 [1.17-4.08] * 4.1 6.91 [1.03-46.32] * 3.1 4.22 [0.84-21.17] ¶ 
 IDU males  27.6 0.95 [0.33-2.73] 9.2 2.78 [0.32-24.08] 9.1 9.53 [0.32-284.21] 
 IDU females  17.3 0.41 [0.09-1.79] 0 - 4.4 3.23 [0.07-150.78] 
Age (years)  <30  29.5 1.02 [0.48-2.18] 0 - 2.9 4.75 [0.40-56.29] 
 30-39  22.1 1 4.2 1 1.4 1 
 40-49  17.3 0.82 [0.51-1.32] 3.0 0.69 [0.21-2.22] 3.6 1.69 [0.45-6.39] 
 ≥50  16.8 1.10 [0.65-1.88] 4.0 1.88 [0.48-7.31] 4.5 5.09 [1.03-25.21] * 
Period of HIV diagnosis <1996  19.9 1 5.1 1 5.0 1 
 ≥1996  19.5 0.90 [0.52-1.55] 2.7 0.37 [0.09-1.60] 1.9 076 [0.20-2.91] 
Time spent on HAART 6-12 months  34.2 2.97 [1.39-6.34] * 5.7 2.16 [0.53-8.74] 0 - 
 12-24 months  28.3 2.50 [1.28-4.86] * 4.0 1.35 [0.36-5.07] 2.3 0.20 [0.03-1.45] 
 24-60 months  17.1 1.15 [0.66-2.02] 2.9 1.15 [0.40-3.32] 2.0 0.26 [0.09-0.79] * 
 >60 months  16.5 1 3.5 1 5.6 1 
CD4 cell count at start of HAART >350  25.7 1 1.6 1 0.8 1 
(/mm3) 201-350  20.1 0.61 [0.36-1.02] ¶ 1.2 0.73 [0.12-4.62] 0.7 0.96 [0.09-9.72] 
 51-200  19.3 0.67 [0.39-1.14] 5.1 3.19 [0.61-16.78] 7.1 6.18 [1.54-24.76] * 
 ≤50  10.4 0.44 [0.19-0.99] * 7.1 7.88 [1.50-41.51] * 9.7 11.49 [1.87-70.66] * 
HIV RNA at start of HAART <10 000   29.1 1 3.4 1 1.2 1 
(copies/ml) 10 000-29 999  28.7 1.00 [0.50-2.01] 1.8 0.82 [0.09-7.52] 1.3 1.88 [0.18-20.10] 
 30 000-100 000   18.0 0.60 [0.32-1.09] ¶ 1.2 0.23 [0.04-1.47] 4.1 2.60 [0.35-19.13] 
 ≥100 000  15.2 0.53 [0.30-0.94] * 5.1 1.64 [0.37-7.26] 3.6 2.06 [0.32-13.37] 
 Unknown  22.3 1.09 [0.41-2.90] 1.4 0.76 [0.05-11.88] 0 - 
AIDS at start of HAART No  22.3 1 3.2 1   
 Yes  11.0 0.60 [0.34-1.07] ¶ 4.2 0.45 [0.17-1.18]   
 Unknown  20.2 0.32 [0.02-6.21] 0 -   
History of interruption in HIV care No  18.8 1 2.8 1 2.3 1 
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 Yes  27.5 1.82 [0.86-3.84] 10.8 3.11 [0.54-17.96] 10.1 5.45 [1.26-23.60] * 
 Unknown  41.6 2.92 [0.05-170.94] 23.2 19.95 [1.00-399.16] * 0 - 
Adherence to HAART High  14.0 1 2.5 1 2.0 1 
 Poor  28.1 1.87 [1.27-2.76] * 4.8 2.01 [0.89-4.52] ¶ 4.4 2.60 [0.88-7.62] ¶ 
HCV coinfection No  17.8 1 3.1 1 2.5 1 
 Yes  28.4 2.13 [1.04-4.38] * 5.2 0.39 [0.11-1.42] 5.1 0.42 [0.02-7.57] 
Depressive symptoms No  18.0 1 3.4 1 2.3 1 
 Mild  21.0 0.92 [0.45-1.91] 2.9 0.35 [0.08-1.57] 7.2 2.95 [0.73-11.86] 
 Moderate or severe  23.0 1.00 [0.42-2.41] 9.8 3.55 [0.75-16.96] 6.0 4.33 [0.53-35.29] 
 Unknown  22.9 1.05 [0.65-1.69] 2.7 0.43 [0.14-1.33] 2.6 0.74 [0.20-2.75] 
Current drug use No  19.2 1 3.0 1 2.9 1 
 Yes  31.1 1.26 [0.43-3.73] 20.0 13.36 [1.38-129.66] * 4.7 0.28 [0.03-3.00] 
 
OR: odds-ratio CI: confidence interval 
IDU: intravenous drug users 
* p<0.05 ¶ p<0.10 
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